Sepsis and severe infections

9 April, 2025

The EMBRACE trial at the 44th International Symposium of Intensive Care and Emergency Medicine

2025-04-09T09:31:05+03:00By hiss|Categories: Publications, Sepsis and severe infections|Tags: emapalumab, Interferon-gamma, poster, Studies on Sepsis and severe infections|

Ourania Konstantinidou, Elisavet Olntasi, Helena Florou, Souzana Anisoglou, Eleni Antoniadou, George Dimopoulos, Eleni Gkeka, Aikaterini Ioakeimidou, Vassileios Karamouzos, Efmorphia Kondili, Zafeiria Mastora, Eleni Mouloudi, Pavlos Myrianthefs, Maria Ntaganou, Elissavet Paramythiotou, Vassilis Papaioannou, Maria Patrani, Nikoletta Rovina, Glykeria Vlachogianni, Armin J. Reininger, Evangelos J. Giamarellos-Bourboulis 44th International Symposium of Intensive Care and Emergency

12 March, 2025

EMBRACE

2025-04-09T09:25:03+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: emapalumab, IFNγ, infections, Sepsis|

Ongoing study Official Study Title EMapalumaB treatment foR Anticipated Clinical benefit in sepsis driven by the Interferon-Gamma Endotype (The EMBRACE trial) Brief Description In a recent analysis of 5,503 patients with sepsis meeting the Sepsis-3 definitions and coming from Germany, Greece and Italy randomized into one discovery set and one validation set, it was

27 December, 2024

POINT study

2025-01-09T10:44:40+03:00By hiss|Categories: Non-Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: complications, COVID-19, post-acute, prevention|

Personalised care for post-COVID-19 health Connect to the official POINT website Ongoing study Official Study Title A non-interventional, Prospective, cross-sectional study Of the INcidence of pulmonary, cardiovascular and renal system non-communicable complications associated with the post-acute phase of the infecTion by SARS-CoV-2 Brief Description POINT is an innovative research project funded

29 November, 2024

HOMI-LUNG CAP

2025-01-09T10:15:28+03:00By hiss|Categories: Non-Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: cardiovascular, COVID-19, pneumonia|

A STRONG CONSORTIUM TO FILL THE GAP Pneumonia is a heart matter too (and viceversa) Connect to the official HOMI-LUNG CAP website Ongoing study Official Study Title A non-interventional, prospective, cross-sectional study of cardiovascular disease progression in survivors of community acquired pneumonia and lung infection by SARS-CoV-2 Brief Description HOMI-LUNG is

13 February, 2024

REACT

2025-03-13T15:59:08+03:00By hiss|Categories: Ongoing, Sepsis and severe infections, Studies|Tags: CAP, clarithromycin, pneumonia, Sepsis, suPAR|

Ongoing study Official Study Title BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial Brief Description The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of

1 September, 2023

PRECISION

2024-12-11T10:32:19+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

HISS: Facing the LONG-COVID syndrome Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The

15 February, 2023

MODIFY

2024-11-04T11:36:45+03:00By hiss|Categories: Ongoing, Sepsis and severe infections, Studies|Tags: procalcitonin, Sepsis|

Ongoing study Official Study Title A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial) Brief Description The aim of the study is to demonstrate if using a combined strategy of rapid molecular diagnosis with BioFire® FilmArray® Blood Culture Identification 2 Panel and

1 February, 2023

HDM-FUN-Candidemia

2024-01-03T16:56:31+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: candidemia|

Ongoing study Official Study Title Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia: The HDM-FUN-Candidemia trial Brief Description Invasive fungal infections are an important cause of morbidity and mortality and lead to numerous hospital and ICU admissions. Candidemia is associated with a suppressed immune status

10 January, 2023

SAVE-LONG

2023-05-22T14:50:00+03:00By hiss|Categories: Non-Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: COVID-19|

Ongoing study Official Study Title Symptom-guided Anakinra treatment for the Validation of immunE dysfunction persisting for LONG after hospital discharge for COVID-19 (SAVE-LONG) Brief Description SAVE-LONG is a call to the development of diagnostic tools and therapeutic modalities for patients with Long-COVID Syndrome. Details Status: ongoing Study Type: Non-interventional Study phase: II &

10 October, 2022

INSPIRE

2024-11-04T11:14:45+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: Anakinra, pneumonia|

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard